LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway
2024 · Journal of Experimental & Clinical Cancer Research · 17 citations
https://doi.org/10.1186/s13046-024-03110-y
H
Hongying Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
54
Papers
34
Citations
3
h-index
2
i10-index
Hongying Wang is an academic researcher from Binzhou Medical University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lymphoma Diagnosis and Treatment & Immune Cell Function and Interaction. The author has an h-index of 3, co-authored 46 publications.
ORCID: 0000-0002-3963-1155Papers by this author
worksFigure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.27028771.v1
Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.27028768.v1
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.27028774.v1
Figure S4 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.27028783.v1
Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · 0 citations
https://doi.org/10.1158/0008-5472.27028780.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat